Sort   by:  
 Page size 
ProteomicsReshaping of the MHC-I ligandome in response to reovirus-based cancer immunotherapy
Oncolytic viruses (OVs), known for their cancer-killing characteristics, overturn tumor-associated defects in antigen presentation through the MHC class I pathway and induce protective neo antitumor CD8 T cell responses. Nonetheless, whether OVs shape the tumor MHC-I ligandome remains unknown. Here,...
ORGANISM(S): Mus musculus (Mouse) 
2019-05-20 | PXD013066 | Pride
Antitumor immunity Reovirus Mhc ligandome Mass spectrometry Cancer immunotherapy Cd8 t cell epitopes Oncolytic virus 
ProteomicsMouse TAPBPR functions as an MHC-I peptide exchange catalyst
Human TAPBPR is known to function as a Major Histocompatibility Complex class I (MHC-I) peptide exchange catalyst which shapes the peptide repertoire presented to immune cells. Never14theless, investigations characterizing TAPBPR from other species are limited. Here, we characterize mouse TAPBPR, ex...
ORGANISM(S): Mus musculus (Mouse) 
2026-03-23 | PXD069965 | Pride
Mouse Tapbpr Immunopeptidomics Mhc-i Lc-ms/ms 
ProteomicsQuantitative cell type specific immunopeptidome analysis during macrophage and tumor co-evolution reveals therapeutic MHC-I restricted peptides in glioblastoma
Glioblastoma treatment by immunotherapy is limited by the immunosuppresive tumor microenvironment, in part created by GBM associated macrophages. To uncover targetable MHC-I peptides for targeted immunotherapy, we performed cell type specific immunopeptidome analysis on primary macrophages and GBM t...
ORGANISM(S): Mus musculus (Mouse) 
2025-09-03 | PXD057588 | Pride
Tumor associated macrophage Mhc-i restricted peptides Glioblastoma Immunopeptidome 
ProteomicsTargeted delivery of tumor necrosis factor in combination with lomustine induces a T-cell dependent regression of glioblastoma
Glioblastoma is the most aggressive primary brain tumor with an unmet need for more effective therapies. Here we report that the combination of L19TNF, an antibody-cytokine fusion protein based on tumor necrosis factor that selectively localizes on the tumor neo-vasculature, with the alkylating ag...
ORGANISM(S): Mus musculus (Mouse) 
2023-06-01 | PXD041256 | Pride
Immunotherapy mhc-i Immunopeptidomics 
GenomicsTumor NLRP3 Amplification Promotes Immunotherapy Resistance by Inhibiting STAT1 Signaling and Suppressing MHC Class I Expression
Tumor NLRP3 Amplification Promotes Immunotherapy Resistance by Inhibiting STAT1 Signaling and Suppressing MHC Class I Expression
PRJNA1468151 | ENA
ProteomicsCombining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma
Checkpoint immunotherapy unleashes tumor control by T cells, but it is undermined in non-immunogenic tumors, e.g. with low MHC class I expression and low neoantigen burden, such as neuroblastoma (NB). Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an enzyme that trims peptides before loading on M...
ORGANISM(S): Mus musculus (Mouse) 
2025-05-07 | PXD055268 | Pride
Mhc Immunotherapy Neuroblastoma Immunopeptidomics Erap 
ProteomicsLC-MSMS of the MHC-I immunopeptidome of human melanoma
While immune checkpoint blockade (ICB) therapy has significantly improved the outcome of metastatic melanoma and non-small cell lung cancer (NSCLC), most patients do not derive long-term benefits. Previous studies suggest that treatment failure is partly due to insufficient immune recognition of tum...
ORGANISM(S): Homo sapiens (Human) 
2025-02-19 | PXD043059 | Pride
Lc-msms Melanoma Immunopeptidome Mhc class i 
GenomicsCD4+ T cell-licensed CD8+ T cells drive immunotherapy response in MHC-I negative MMRd cancer
CD4+ T cell-licensed CD8+ T cells drive immunotherapy response in MHC-I negative MMRd cancer
PRJNA1465373 | ENA
ProteomicsLC-MSMS of the MHC-I immunopeptidome of human NSCLC samples
While immune checkpoint blockade (ICB) therapy has significantly improved the outcome of metastatic melanoma and non-small cell lung cancer (NSCLC), most patients do not derive long-term benefits. Previous studies suggest that treatment failure is partly due to insufficient immune recognition of tum...
ORGANISM(S): Homo sapiens (Human) 
2025-02-19 | PXD043057 | Pride
Non-small cell lung cancer Lc-msms Immunopeptidome Mhc class i 
ModelsKronik2008 - Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics
This mathematical model describes interactions between glioma tumors and the immune system that may occur following direct intra-tumoral administration of ex-vivo activated alloreactive cytotoxic-T-lymphocytes (aCTLs) as part of adoptive immunotherapy. The model includes descriptions of aCTL, neopla...
2024-09-02 | BIOMD0000000808 | BioModels
Immuno-oncology 
Sort   by:  
 Page size